Table 1 Patient’s characteristics
From: Risk factors for renal toxicity after inpatient cisplatin administration
N of Patients (%) | |
|---|---|
Sex | |
Male | 106 (58) |
Female | 78 (42) |
Tumor Type | |
Head and neck | 68 (37) |
Genitourinary | 17 (9,5) |
Gynecological | 23 (13) |
Pulmonary | 28 (15) |
Gastrointestinal | 24 (13) |
Hematological | 14 (7,5) |
Breast | 3 (1,5) |
Malignant melanoma | 3 (1,5) |
Thymoma | 2 (1) |
Endocrine | 1 (0,5) |
CNS | 1 (0,5) |
Co morbidity | |
Hypertension | 54 (30) |
Diabetes | 10 (5) |
Cardiopathy | 12 (6) |
Vasculopathy | 19 (10) |
COPD | 21 (11) |
Alcohol abuse | 28 (15) |
Liver Cirrhosis | 4 (2) |
Drugs and other agents | |
ICM during cisplatin | 26 (14) |
Metformin | 5 (3) |
ACE-Inhibitor | 13 (7) |
NSAID | 28 (15) |
Aminoglycosides | 3 (2) |
Glycopeptides | 2 (1) |
Others antibiotics | 36 (19) |